Online citations, reference lists, and bibliographies.
← Back to Search

Systemic Immune‐checkpoint Blockade With Anti‐PD1 Antibodies Does Not Alter Cerebral Amyloid‐β Burden In Several Amyloid Transgenic Mouse Models

Martine Latta-Mahieu, B. Elmer, A. Bretteville, Y. Wang, M. Lopez-Grancha, Philippe Goniot, Nicolas Moindrot, Paul Ferrari, V. Blanc, N. Schussler, Emmanuel Brault, Valérie Roudières, Véronique Blanchard, Zhi-yong Yang, P. Barnéoud, Philippe Bertrand, B. Roucourt, Sofie Carmans, A. Bottelbergs, L. Mertens, C. Wintmolders, P. Larsen, Caroline Hersley, Tyler J McGathey, M. Racke, L. Liu, J. Lu, M. O'Neill, D. Riddell, A. Ebneth, G. Nabel, L. Pradier
Published 2018 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Chronic inflammation represents a central component in the pathogenesis of Alzheimer's disease (AD). Recent work suggests that breaking immune tolerance by Programmed cell Death‐1 (PD1) checkpoint inhibition produces an IFN‐γ‐dependent systemic immune response, with infiltration of the brain by peripheral myeloid cells and neuropathological as well as functional improvements even in mice with advanced amyloid pathology (Baruch et al., ( ): Nature Medicine, 22:135–137). Immune checkpoint inhibition was therefore suggested as potential treatment for neurodegenerative disorders when activation of the immune system is appropriate. Because a xenogeneic rat antibody (mAb) was used in the study, whether the effect was specific to PD1 target engagement was uncertain. In the present study we examined whether PD1 immunotherapy can lower amyloid‐β pathology in a range of different amyloid transgenic models performed at three pharmaceutical companies with the exact same anti‐PD1 isotype and two mouse chimeric variants. Although PD1 immunotherapy stimulated systemic activation of the peripheral immune system, monocyte‐derived macrophage infiltration into the brain was not detected, and progression of brain amyloid pathology was not altered. Similar negative results of the effect of PD1 immunotherapy on amyloid brain pathology were obtained in two additional models in two separate institutions. These results show that inhibition of PD1 checkpoint signaling by itself is not sufficient to reduce amyloid pathology and that additional factors might have contributed to previously published results (Baruch et al., ( ): Nature Medicine, 22:135–137). Until such factors are elucidated, animal model data do not support further evaluation of PD1 checkpoint inhibition as a therapeutic modality for Alzheimer's disease.
This paper references
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
D. Games (1995)
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
R. Radde (2006)
A plaque-specific antibody clears existing beta-amyloid plaques in Alzheimer’s disease
R. B. Demattos (2012)
Microglia contributes to plaque growth by cell death due to uptake of amyloid β in the brain of Alzheimer's disease mouse model
S. H. Baik (2016)
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
J. Schachter (2017)
Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice
T. Loeffler (2013)
Reduced beta-amyloid pathology in an APP
L. Kulic (2015)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Regulatory T cells delay disease progression in Alzheimer-like pathology.
Cira Dansokho (2016)
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
C. Janus (2000)
Time sequence of maturation of dystrophic neurites associated with Aβ deposits in APP/PS1 transgenic mice
V. Blanchard (2003)
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.
K. Johnson-wood (1997)
Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
T. Asberom (2007)
The adaptive immune system restrains Alzheimer’s disease pathogenesis by modulating microglial function
Samuel E. Marsh (2016)
Glial cells as drug targets: What does it take?
T. Möller (2016)
Pathological hallmarks, clinical
L. chi (2010)
Six red flags for suspect
C. G. Begley (2013)
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
K. Baruch (2016)
Pembrolizumab versus ipilimumab for advanced
J. Schachter (2017)
The role of peripheral immune cells in the CNS in steady state and disease
M. Prinz (2017)
Aging Increased Amyloid Peptide and Caused Amyloid Plaques in Brain of Old APP/V717I Transgenic Mice by a Different Mechanism than Mutant Presenilin1
I. Dewachter (2000)
Six red flags for suspect work.
Begley Cg (2013)
Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice
Sandro Alves (2017)
Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer's disease pathology
K. Baruch (2015)
Long-term treatment with liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has no effect on beta-amyloid plaque load in two transgenic APP/PS1 mouse models of Alzheimer’s disease
H. H. Hansen (2016)
Neutrophils promote Alzheimer's disease–like pathology and cognitive decline via LFA-1 integrin
Elena Zenaro (2015)
Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase
J. Jankowsky (2004)
Reproducibility: Six red flags for suspect work
C. G. Begley (2013)
Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid-b burden in several amyloid transgenic mouse models
M Latta-Mahieu (2018)
Evaluation of muPET outcome measures to detect disease modification induced by BACE inhibition in a transgenic mouse model of Alzheimer’s disease
S. Deleye (2017)
IFN-γ Production by Amyloid β–Specific Th1 Cells Promotes Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer’s Disease
Tara C Browne (2013)
A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice
R. Demattos (2012)
Neutrophils promote Alzhei
S. Budui (2015)
Mechanisms of Aβ Clearance and Degradation by Glial Cells
M. Ries (2016)
Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota
T. Harach (2017)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
C. Janus (2000)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
S. Kleffel (2015)
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
Holly Oakley (2006)
Tetrahydroquinoline sulfonamides as γ-secretase inhibitors
T. Asberom (2007)
Evaluation of Small-Animal PET Outcome Measures to Detect Disease Modification Induced by BACE Inhibition in a Transgenic Mouse Model of Alzheimer Disease
S. Deleye (2017)
Innate immunity in Alzheimer's disease
M. Heneka (2015)
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.
J. Jankowsky (2004)
Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
K. Johnson-wood (1997)
Reduced beta - amyloid pathology in an APP transgenic mouse model of Alzheimer ’ s disease lacking functional B and T cells
C. Spani (2015)
IFN-gamma production by amyloid betaspecific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer’s disease
T. C. Browne (2013)
Systemic Transplantation of Human Umbilical Cord Derived Mesenchymal Stem Cells-Educated T Regulatory Cells Improved the Impaired Cognition in AβPPswe/PS1dE9 Transgenic Mice
HongNa Yang (2013)
Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease
H. H. Hansen (2016)
Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells
C. Späni (2015)
Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model
A. Tanghe (2010)
con - tributes to plaque growth by cell death due to uptake of amyloid beta in the brain of Alzheimer ’ s disease mouse model
S. H. Baik (2016)

This paper is referenced by
Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets
Francis J Herman (2019)
Neuroprotective effect of tormentic acid against memory impairment and neuro-inflammation in an Alzheimer's disease mouse model
W. Cui (2020)
PD-1 Regulates GABAergic Neurotransmission and GABA-Mediated Analgesia and Anesthesia
Changyu Jiang (2020)
CD33 in Alzheimer’s Disease – Biology, Pathogenesis, and Therapeutics: A Mini-Review
Lingzhi Zhao (2018)
Peripheral immune system in aging and Alzheimer’s disease
W. Cao (2018)
Passive Immunotherapy in Alzheimer’s Disease
P. J. Dolan (2018)
Lymphocyte activation gene 3 (Lag3) is upregulated by prions but does not contribute to disease
Y. Liu (2018)
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression
Y. Liu (2018)
Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
Y. Lin (2019)
Repositioning of Immunomodulators: A Ray of Hope for Alzheimer’s Disease?
Antonio Munafò (2020)
PD-1 deficiency is not sufficient to induce myeloid mobilization to the brain or alter the inflammatory profile during chronic neurodegeneration
J. Obst (2018)
Response: Commentary: Chronic PD-1 Checkpoint Blockade Does Not Affect Cognition or Promote Tau Clearance in a Tauopathy Mouse Model
Y. Lin (2020)
Interferons: A molecular switch between damage and repair in ageing and Alzheimer’s disease
N. Gorle (2019)
Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer’s disease
B. M. Elmer (2019)
Chapter 8 Passive Immunotherapy in Alzheimer ’ s Disease
P. J. Dolan (2019)
Learning from Principles of Evidence-Based Medicine to Optimize Nonclinical Research Practices.
Isabel A Lefevre (2019)
Inverse Relationship Between Alzheimer's Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases.
Nicole K. Rogers (2019)
Anti-PD-1 treatment as a neurotherapy to enhance neuronal excitability, synaptic plasticity and memory
Junli Zhao (2019)
Immunotherapy for neurodegeneration?
Y. Liu (2019)
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model
Neta Rosenzweig (2019)
Targeting neuro–immune communication in neurodegeneration: Challenges and opportunities
A. Deczkowska (2018)
VISTA expression by microglia decreases during inflammation and is differentially regulated in CNS diseases
M. Borggrewe (2018)
Inhibition of TLR4 Induces M2 Microglial Polarization and Provides Neuroprotection via the NLRP3 Inflammasome in Alzheimer’s Disease
W. Cui (2020)
Influenza vaccine combined with moderate-dose PD1 blockade reduces amyloid-β accumulation and improves cognition in APP/PS1 mice
Zhiwei Xing (2021)
Exploring the VISTA of microglia: immune checkpoints in CNS inflammation
M. Borggrewe (2020)
Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression
Y. Liu (2018)
Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
K. Biber (2019)
Semantic Scholar Logo Some data provided by SemanticScholar